Autolus acquires rights to commercialise novel T-cell therapy developed at GOSH and UCLH

24 Apr 2018, 2:56 p.m.

Professor Persis Amrolia

The biopharmaceutical company Autolus has acquired global rights to develop and commercialize a novel T-cell therapy for the treatment of B-cell lymphomas and leukaemias.The biopharmaceutical company Autolus has acquired global rights to develop and commercialize a novel T-cell therapy for the treatment of B-cell lymphomas and leukaemias. The therapy, known as AUTO1, is currently the subject of two Phase 1 studies: one in paediatric acute lymphoblastic leukaemia (ALL) led by National Institute for Health Research (NIHR) GOSH Biomedical Research Centre (BRC) researcher Professor Persis Amrolia and the other in adult ALL led by Dr Martin Pule at UCL Hospital (UCLH).

Autolus Limited specialises in developing next-generation programmed T-cell therapies and has acquired the rights from UCL Business plc (UCLB), the technology-transfer company of University College London (UCL).

The AUTO1 therapy uses a type of immune cell (T-cells) that have been modified to efficiently recognize and kill cancer cells. The T cells are engineered to express a novel CD19-specific chimeric antigen receptor (CAR), which targets B-cell lymphomas and leukaemia expressing the CD19 protein. AUTO1 is also designed to reduce the risk of cytokine release syndrome - a serious and potentially life-threatening side effect of immunotherapy. In the paediatric ALL study, which was recently presented at the the 2017 Annual Meeting of the American Society of Hematology, investigators observed levels of efficacy similar to those in other reported studies without the need to administer immunosuppressive drugs.

This partnership between UCL Business and Autolus will support the continued development of this promising approach and bring this ground-breaking new treatment one step closer to patients.

Read more: Autolus press release

Young people donate tissue samples to unlock mysteries of arthritis

A new groundbreaking study led by researchers at the University of Birmingham, Great Ormond Street Hospital, University College London and Birmingham Children’s Hospital has revealed important clues into what is driving arthritis in children.

Toddler doing well after receiving newest gene therapy available on NHS

A toddler with a life-limiting and life-threatening rare disease is the youngest to be treated with the newest gene therapy available on the NHS at GOSH.

Genes may help to predict which children will respond well to arthritis treatment

A team of researchers at Great Ormond Street Hospital (GOSH) and University College London (UCL) have identified a set of genes that could be used to help doctors predict which children will respond well to treatment for juvenile idiopathic arthritis.

Making it easier to invest in frontline care

GOSH and UCL have signed a landmark agreement to simplify the commercialisation of any joint research and innovation and ensure any financial proceeds are shared equally.